Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 5/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25388961 | 0.91 | LMNA (0.40) | SMN1; SMN2KDM4ETSHRLMNAMAPT | |
| SCHEMBL25389772 | 0.88 | GPR119 (0.39) | SMN1; SMN2KDM4ETSHRLMNAMAPT | |
| SCHEMBL26238724 | 0.86 | ADRA1A (0.43) | TSHRLMNAMAPTALDH1A1 | |
| SCHEMBL26238713 | 0.86 | LMNA (0.42) | SMN1; SMN2KDM4ETSHRLMNAKMT2A | |
| SCHEMBL26238734 | 0.86 | AKR1C3 (0.46) | — | |
| SCHEMBL26238705 | 0.86 | KDM4E (0.39) | SMN1; SMN2KDM4ELMNAMAPTTP53 | |
| SCHEMBL26238630 | 0.86 | KDM4E (0.42) | SMN1; SMN2KDM4ELMNAMAPTKMT2A | |
| SCHEMBL25387649 | 0.86 | BDKRB1 (0.43) | TSHRLMNAMAPTKMT2ACYP2C9 | |
| SCHEMBL25387883 | 0.85 | MAPT (0.41) | SMN1; SMN2MAPTKMT2AMEN1ALDH1A1 | |
| SCHEMBL25389204 | 0.85 | GPR119 (0.39) | SMN1; SMN2KDM4ETSHRLMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250280861-A1 | SWEETENER COMPOSITIONS | FIRMENICH INCORPORATED (US) | 2025-09-11 | — | — | US | disclosed |
| EP-4472947-A1 | SWEETENER COMPOSITIONS | Firmenich Incorporated (US) | 2024-12-11 | — | — | EP | disclosed |
| WO-2023172415-A1 | SWEETENER COMPOSITIONS | FIRMENICH INCORPORATED (US) | 2023-09-14 | — | — | WO | disclosed |
| WO-2023172415-A1 | SWEETENER COMPOSITIONS | FIRMENICH INCORPORATED (US) | 2023-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250280861-A1 | SWEETENER COMPOSITIONS | GPR119, TAS2R50, TAS2R30 | SMN1; SMN2 1171/4885KDM4E 4072/4885TSHR 3705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.